Cancer Research 09 AM Call for Abstracts  SU2C
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tanaka, F.
Right arrow Articles by Tahara, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanaka, F.
Right arrow Articles by Tahara, H.
[Cancer Research 60, 4838-4844, September 1, 2000]
© 2000 American Association for Cancer Research


Immunology

Rapid Generation of Potent and Tumor-specific Cytotoxic T Lymphocytes by Interleukin 18 Using Dendritic Cells and Natural Killer Cells1

Fumiaki Tanaka, Wataru Hashimoto, Haruki Okamura, Paul D. Robbins, Michael T. Lotze and Hideaki Tahara2

Departments of Surgery [F. T., W. H., M. T. L., H. T.] and Molecular Genetics and Biochemistry [F. T., W. H., P. D. R., M. T. L., H. T.], University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, and Division of Host Defenses, Institution for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan [H. O.]

We hypothesized that antitumor-specific immunity, which is induced by interleukin (IL) 18 treatment in murine tumor models, is promoted by enhancing natural killer (NK)-mediated destruction of tumor and delivery to dendritic cells (DCs). These activated and antigen-pulsed DCs then critically and optimally induce an adoptive immune response, positioning IL-18 as an important bridge between the innate and adoptive immune response. The effect of IL-18 added to cultures of live tumor cells (MCA205, a mouse sarcoma cell line), NK cells, DCs, and T cells was assessed. When recombinant (r) mIL-18 protein was added to this culture, potent NK cytolytic activity with subsequent generation of CTLs was observed in a dose-dependent manner. Without introduction of either rmIL-18 or NK cells into this culture, systemic cytolytic activity was significantly decreased. Following the absence of direct contact of either NK cells or DCs with other cells in this cooperative coculture system using transwell, the systemic cytolytic activity of both NK cells and CTLs was greatly suppressed. The cytolysis mediated by effector cells harvested after completion of the culture was primarily restricted to MHC class I and highly specific for the tumor cells used in the coculture. Furthermore, we examined the efficiency in the induction of cytolytic T cells of other established IFN-{gamma} inducing T-cell growth factors, IL-2, and IL-12 in this culture system and compared them with that mediated by IL-18. Neither IL-2 nor IL-12 induced tumor-specific cytolytic T cells to the same degree as that mediated by IL-18. Efficacy of this system in induction of tumor-specific CTLs was also observed in the system using MC38 adenocarcinoma cells. These results are consistent with the notion that IL-18 induces tumor-specific immunity through enhancing NK activity, which in turn mediates tumor cell death and activates and primes DCs.




This article has been cited by other articles:


Home page
J. Leukoc. Biol.Home page
A. Iannello, O. Debbeche, S. Samarani, and A. Ahmad
Antiviral NK cell responses in HIV infection: I. NK cell receptor genes as determinants of HIV resistance and progression to AIDS
J. Leukoc. Biol., July 1, 2008; 84(1): 1 - 26.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. Iannello, O. Debbeche, S. Samarani, and A. Ahmad
Antiviral NK cell responses in HIV infection: II. viral strategies for evasion and lessons for immunotherapy and vaccination
J. Leukoc. Biol., July 1, 2008; 84(1): 27 - 49.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. J. Robertson, J. W. Mier, T. Logan, M. Atkins, H. Koon, K. M. Koch, S. Kathman, L. N. Pandite, C. Oei, L. C. Kirby, et al.
Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
Clin. Cancer Res., July 15, 2006; 12(14): 4265 - 4273.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. N. MacGregor, Q. Li, A. E. Chang, T. M. Braun, D. P.M. Hughes, and K. T. McDonagh
Ex vivo Culture with Interleukin (IL)-12 Improves CD8+ T-Cell Adoptive Immunotherapy for Murine Leukemia Independent of IL-18 or IFN-{gamma} but Requires Perforin.
Cancer Res., May 1, 2006; 66(9): 4913 - 4921.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. Ahmad and F. Alvarez
Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis
J. Leukoc. Biol., October 1, 2004; 76(4): 743 - 759.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Ribas, J. A. Wargo, B. Comin-Anduix, S. Sanetti, L. Y. Schumacher, C. McLean, V. B. Dissette, J. A. Glaspy, W. H. McBride, L. H. Butterfield, et al.
Enhanced Tumor Responses to Dendritic Cells in the Absence of CD8-Positive Cells
J. Immunol., April 15, 2004; 172(8): 4762 - 4769.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Massa, C. Guiducci, I. Arioli, M. Parenza, M. P. Colombo, and C. Melani
Enhanced Efficacy of Tumor Cell Vaccines Transfected with Secretable hsp70
Cancer Res., February 15, 2004; 64(4): 1502 - 1508.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
K. Mashino, N. Sadanaga, F. Tanaka, M. Ohta, H. Yamaguchi, and M. Mori
Effective Strategy of Dendritic Cell-based Immunotherapy for Advanced Tumor-bearing Hosts: the Critical Role of Th1-dominant Immunity
Mol. Cancer Ther., August 1, 2002; 1(10): 785 - 794.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. G. Veenstra, Z. L. Jonak, S. Trulli, and J. A. Gollob
IL-12 Induces Monocyte IL-18 Binding Protein Expression Via IFN-{gamma}
J. Immunol., March 1, 2002; 168(5): 2282 - 2287.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.